Christopher Alafi Biography and Net Worth

Director of Intra-Cellular Therapies

Dr. Christopher D. Alafi Ph.D. is an Independent Director of Intra-Cellular Therapies, Inc. Dr. Alafi became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since January 2013. Dr. Alafi has been a Managing Partner of Alafi Capital Company, LLC, a venture capital firm and a principal stockholder of the Company, since 1995. He was previously a Physiology and Anatomy teacher at Santa Monica College, a visiting scholar in the Department of Chemistry at Stanford University and a researcher at DNAX. Dr. Alafi previously served as a director of ISTO Technologies, Coley Pharmaceutical Group, Inc., CyberGold, Inc. and Stereotaxis, Inc. Dr. Alafi received a B.A. in Biology from Pomona College and a D.Phil. in Biochemistry from the University of Oxford.

What is Christopher D. Alafi's net worth?: The estimated net worth of Christopher D. Alafi is at least $24.96 million as of May 27th, 2021. Dr. Alafi owns 346,795 shares of Intra-Cellular Therapies stock worth more than $24,958,836 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Alafi may own. Learn More about Christopher D. Alafi's net worth.
How do I contact Christopher D. Alafi?: The corporate mailing address for Dr. Alafi and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Christopher D. Alafi's contact information.
Has Christopher D. Alafi been buying or selling shares of Intra-Cellular Therapies?: Christopher D. Alafi has not been actively trading shares of Intra-Cellular Therapies during the last ninety days. Most recently, Christopher D. Alafi sold 8,482 shares of the business's stock in a transaction on Thursday, May 27th. The shares were sold at an average price of $40.01, for a transaction totalling $339,364.82. Following the completion of the sale, the director now directly owns 346,795 shares of the company's stock, valued at $13,875,267.95. Learn More on Christopher D. Alafi's trading history.
Who are Intra-Cellular Therapies' active insiders?: Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.
Are insiders buying or selling shares of Intra-Cellular Therapies?: During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 682,285 shares worth more than $43,934,823.19. The most recent insider tranaction occured on March, 11th when CEO Sharon Mates sold 20,565 shares worth more than $1,341,043.65. Insiders at Intra-Cellular Therapies own 3.4% of the company. Learn More about insider trades at Intra-Cellular Therapies.
Information on this page was last updated on 3/11/2024.

Christopher D. Alafi Insider Trading History at Intra-Cellular Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/27/2021	Sell	8,482	$40.01	$339,364.82	346,795
5/24/2021	Sell	26,575	$40.47	$1,075,490.25	346,795
5/21/2021	Sell	1,100	$40.00	$44,000.00	346,795
9/14/2020	Buy	49,500	$29.60	$1,465,200.00	345,223
9/11/2020	Buy	21,000	$28.08	$589,680.00
9/10/2019	Buy	485,000	$10.26	$4,976,100.00	341,223
8/30/2019	Buy	125,000	$8.52	$1,065,000.00	341,223
6/12/2019	Buy	170,000	$11.73	$1,994,100.00	750,106
5/14/2019	Buy	100,000	$12.56	$1,256,000.00	750,106
12/29/2017	Buy	1,001	$14.48	$14,494.48
11/22/2017	Buy	10,000	$15.55	$155,500.00	744,466
11/14/2016	Buy	34,000	$14.50	$493,000.00	730,529
2/29/2016	Buy	100,000	$29.70	$2,970,000.00	728,828
3/11/2015	Buy	625,000	$24.00	$15,000,000.00
11/28/2014	Buy	35,000	$14.75	$516,250.00

Christopher D. Alafi Buying and Selling Activity at Intra-Cellular Therapies

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $71.97

$71.35

$72.78

50 Day Range

MA: $69.44

$64.37

$79.84

2 Week Range

Now: $71.97

$45.50

$84.89

Volume

325,023 shs

Average Volume

938,664 shs

Market Capitalization

$6.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…